| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8313466 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 2 months from now) | |
| US7918823 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 2 months from now) | |
| US10737028 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 2 months from now) | |
| US9737669 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 2 months from now) | |
| US8425462 | KALEO INC | Devices, systems, and methods for medicament delivery |
Nov, 2024
(1 year, 2 months from now) | |
| US9056170 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 2 months from now) | |
| US8361029 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 2 months from now) | |
| US8608698 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 2 months from now) | |
| US10314977 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(1 year, 2 months from now) | |
| US7731690 | KALEO INC | Devices, systems and methods for medicament delivery |
Jan, 2025
(1 year, 3 months from now) | |
| US8016788 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2025
(1 year, 5 months from now) | |
| US10335549 | KALEO INC | Devices, systems and methods for medicament delivery |
Apr, 2025
(1 year, 7 months from now) | |
| US11590286 | KALEO INC | Devices, systems and methods for medicament delivery |
Dec, 2026
(3 years from now) | |
| US7947017 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2028
(4 years from now) | |
| US10322239 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(7 years from now) | |
| US9814838 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(7 years from now) | |
| US9474869 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(7 years from now) | |
| US8939943 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(7 years from now) | |
| US9022022 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(7 years from now) | |
| US10143792 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
May, 2031
(7 years from now) | |
Naloxone Hydrochloride (Autoinjector) is owned by Kaleo Inc.
Naloxone Hydrochloride (Autoinjector) contains Naloxone Hydrochloride.
Naloxone Hydrochloride (Autoinjector) has a total of 20 drug patents out of which 0 drug patents have expired.
Naloxone Hydrochloride (Autoinjector) was authorised for market use on 28 February, 2022.
Naloxone Hydrochloride (Autoinjector) is available in solution;intramuscular, subcutaneous dosage forms.
Naloxone Hydrochloride (Autoinjector) can be used as use of a delivery device to deliver a dose of naloxone, use of a delivery device to administer a dose of naloxone.
The generics of Naloxone Hydrochloride (Autoinjector) are possible to be released after 24 May, 2031.
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 February, 2022
Treatment: Use of a delivery device to administer a dose of naloxone; Use of a delivery device to deliver a dose of naloxone
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
NALOXONE HYDROCHLORIDE (AUTOINJECTOR) family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic